CASRAI Dictionary

Tag: is medrxiv peer reviewed

  • Is medRxiv Reputable? Screening vs bioRxiv Explained

    medRxiv is a reputable, non-profit preprint server for medicine and the health sciences, co-founded in 2019 by Cold Spring Harbor Laboratory, Yale University and BMJ, and since March 2025 operated by the independent non-profit openRxiv. It is reputable as a rapid-dissemination archive, not as a substitute for peer review: every preprint carries an explicit warning that it has not been certified by peer review and must not be used to guide clinical practice.

    medRxiv is defined by its own operators as an online repository for preprints — complete but unpublished manuscripts — in medicine, clinical research and related health sciences, distributed free of charge before formal peer review.

    What screening does medRxiv apply before posting a preprint?

    medRxiv operates a screening process, not a peer-review process. Submissions are checked by in-house staff and an affiliate network of scientists and clinicians for plagiarism, non-scientific content, and material that could plausibly cause harm if acted on before formal review. Manuscripts that pass screening are posted unedited and unproofed, exactly as submitted, with an author-supplied DOI-bearing record that remains permanently linked to any later journal publication.

    This is a materially lighter bar than peer review. medRxiv’s own FAQ states plainly that submissions “are not certified by scientific peer review, edited, or typeset before being posted online,” and that they “may contain errors and/or omissions.” The screening exists to filter out fraud and clearly dangerous content — not to validate methodology, statistics or conclusions.

    How does medRxiv’s screening differ from bioRxiv’s?

    medRxiv and bioRxiv share governance, infrastructure and an operator (openRxiv) but apply different levels of scrutiny because their content carries different real-world risk. bioRxiv covers basic and translational biology — work several steps removed from direct patient action. medRxiv covers clinical trials, epidemiological studies, case reports and public-health research that a patient, clinician or journalist could misread as actionable guidance the same day it is posted.

    As a result, medRxiv layers an additional clinical-risk screen onto the standard plagiarism and legitimacy checks, and it carries a more prominent, standardised disclaimer banner than bioRxiv’s — one that explicitly tells readers not to use the content “to guide clinical practice or health-related behaviour” and not to report it “in news media as established information.” That distinction matters for how research offices and communications teams should treat the two archives when advising authors or fielding press enquiries.

    Feature medRxiv bioRxiv
    Subject scope Clinical, epidemiological and health-sciences research Basic and translational biology
    Additional clinical-risk screen Yes — checks for content that could pose a direct health risk Not applied in the same form
    Clinical-guidance disclaimer Prominent, standardised warning banner on every preprint Standard preprint notice, less clinically specific
    Operator (since March 2025) openRxiv (non-profit) openRxiv (non-profit)

    Is medRxiv peer reviewed, and is it indexed in PubMed?

    No. medRxiv preprints are not peer reviewed at the point of posting. medRxiv is, however, indexed by Crossref, Google Scholar, Semantic Scholar, Europe PubMed Central, and Web of Science’s Preprint Citation Index. Preprints reporting research funded by the U.S. National Institutes of Health are separately indexed in PubMed under NIH public-access requirements — but general medRxiv posting alone does not confer PubMed indexing, and medRxiv is not itself a journal with an impact factor.

    Citation practice already reflects this ambiguity in the literature. A 2022 peer-reviewed study published via PubMed Central found that, among 205 COVID-19 research articles published in four major medical journals in 2020, 60 articles — 29.3% — cited at least one medRxiv preprint, and a meaningful share of those citations pointed to a version that had since been superseded by a peer-reviewed publication elsewhere. That gap between what was cited and what was current is precisely the reputational risk research offices need to manage.

    What misinformation risks come from premature clinical findings?

    The pandemic demonstrated the two-edged nature of clinical preprints. medRxiv and bioRxiv were, in the words of researchers tracking the period, major sources for the rapid dissemination of COVID-19 research — a genuine public-health benefit when speed mattered. But the same speed let unreviewed clinical claims reach journalists, policymakers and the public before methodological flaws could be caught, corrected or retracted.

    • Findings can change materially between preprint and peer-reviewed publication — in titles, data or conclusions.
    • Small, uncontrolled or statistically underpowered clinical studies can circulate as if settled, particularly when picked up by non-specialist media.
    • Preprints are citable and DOI-bearing, which can lend an unwarranted appearance of permanence to findings that were never independently verified.

    This is why medRxiv’s disclaimer is not boilerplate: it is the archive’s primary defence against exactly the misuse pattern institutions most need to guard against — a preliminary clinical finding treated as established fact.

    Frequently asked questions

    Is medRxiv trustworthy?

    medRxiv is trustworthy as an archive, run by credible non-profit institutions with documented screening for plagiarism, legitimacy and health-risk content. It is not trustworthy as a source of validated clinical conclusions, because no submission is peer reviewed before it is posted.

    Who owns medRxiv?

    medRxiv was founded in 2019 by Cold Spring Harbor Laboratory, Yale University and BMJ. Cold Spring Harbor Laboratory operated the site until 11 March 2025, when ownership transferred to openRxiv, a newly formed non-profit dedicated to running both medRxiv and bioRxiv independently.

    Is medRxiv peer-reviewed?

    No. medRxiv preprints are screened, not peer reviewed. Screening checks for plagiarism, non-scientific content and material that could pose a health risk; it does not evaluate methodology, statistical validity or the soundness of a paper’s conclusions the way journal peer review does.

    Is a preprint a reliable source?

    A preprint can be a useful early indicator but is not a finished, validated source. Readers should treat preprint findings as provisional, check whether a peer-reviewed version now exists, and avoid citing preprints as if their conclusions were already established.

    What this means for research offices

    Research offices, communications teams and institutional leaders engaging with medRxiv content should build the following into standard practice:

    • Check publication status before external use. Search for a peer-reviewed version before citing, quoting or promoting a medRxiv finding externally.
    • Retain the disclaimer in any repost. If a preprint is shared via institutional channels, carry medRxiv’s own caution alongside it, not a paraphrased or softened version.
    • Brief media-facing staff explicitly. Journalists and public-affairs teams should be told, in advance, that a medRxiv posting is not equivalent to journal publication.
    • Track the DOI, not just the PDF. medRxiv assigns a persistent DOI to each version, which allows an institution to monitor whether a later, revised or peer-reviewed version supersedes the one initially shared.

    Conclusion: a legitimate archive, not a clinical authority

    medRxiv is reputable in the narrow, correct sense of that word: it is a legitimate, non-profit, well-governed repository operated by credible academic and publishing institutions, with a documented screening process and broad indexing across scholarly databases. It is not, and does not claim to be, a peer-reviewed journal, and its content should never be treated as clinical guidance. The distinction between “reputable archive” and “validated clinical evidence” is the single fact every research office, journalist and clinician needs to carry away from any encounter with a medRxiv preprint.

    For related terminology and role definitions used across the scholarly-communication ecosystem, see the CASRAI Dictionary.

  • Is bioRxiv Peer-Reviewed? What Screening Checks

    bioRxiv preprints are not peer-reviewed. Every submission passes a basic screening process — checked for plagiarism, offensive or non-scientific content, and research-integrity or biosecurity concerns — before posting, usually within 24-48 hours. That screening confirms a manuscript is a genuine, appropriately scoped scientific report; it does not evaluate whether the methods are sound, the data support the conclusions, or the findings are correct. Formal peer review only happens later, if and when the manuscript is submitted to a journal or an independent review service.

    bioRxiv is a free preprint server for the life sciences, operated by the non-profit openRxiv and founded by Cold Spring Harbor Laboratory in 2013, that lets researchers post manuscripts publicly before or during journal submission.

    What bioRxiv’s screening process actually checks

    bioRxiv runs a documented two-step screen on every submission. The first pass is done by in-house staff with scientific and editorial backgrounds, who confirm the manuscript is complete, correctly formatted, and within the server’s life-sciences scope. This stage automatically checks for plagiarism and rules out content that is not a research article — news items, advertisements, policy statements, narrative reviews, and protocols without new data are all excluded.

    The second pass is carried out by bioRxiv Affiliates, a network of volunteer principal investigators, who confirm the work is genuine biological research and flag anything that could pose a public-health or biosecurity risk, including what the US National Institutes of Health defines as dual-use research of concern. Overtly identifying patient information is also removed at this stage.

    • Plagiarism detection against published and preprint literature
    • Confirmation the submission is a scientific research article, not opinion, protocol, or promotional content
    • Dual-use and public-health risk screening by volunteer affiliates
    • Removal of overt patient- or participant-identifying material
    • Scope check — routing clinical-research submissions to medRxiv where appropriate

    bioRxiv’s own documentation states that roughly 5% of submissions do not clear this screen and are not posted. Screening typically completes within 24-48 hours — a fraction of the weeks or months a journal’s peer review takes, which is the entire point of a preprint server.

    Screening vs peer review: what’s the difference

    Screening is a gatekeeping check on form and conduct. Peer review is an expert evaluation of scientific substance — whether the experimental design supports the stated conclusions, whether statistics are applied correctly, and whether the work advances the field. bioRxiv is explicit that no endorsement of an article’s methods, assumptions, conclusions, or scientific quality is implied by its appearance on the server.

    Dimension bioRxiv screening Formal peer review
    Who performs it In-house staff + volunteer affiliates Independent subject-matter expert reviewers
    What it checks Plagiarism, scope, ethics, biosecurity, format Methodology, data integrity, validity of conclusions
    Typical duration 24-48 hours Weeks to several months
    Outcome Posted or rejected (~5% rejected) Accept, revise, or reject a specific journal submission
    Result on the record A citable preprint with a DOI A certified, published journal article

    Some preprints do receive structured external review while still hosted as preprints — eLife launched its Preprint Review service on bioRxiv in May 2020, and services such as Review Commons operate similarly. These are useful signals, but they are separate, named services layered on top of bioRxiv, not a function of bioRxiv’s own screening.

    Independent research (Abdill & Blekhman, cited widely including on Wikipedia) has found that roughly two-thirds of bioRxiv preprints are eventually published in a peer-reviewed journal, and bioRxiv automatically links to the published version once a match is found. That figure is a useful proxy for eventual quality, but it says nothing about the third that are never formally reviewed, and it cannot be applied to any single preprint you are reading today.

    Is medRxiv peer-reviewed too?

    No. medRxiv, bioRxiv’s sister server for clinical and health-related research, follows the same principle: manuscripts are screened, not peer-reviewed. Because medRxiv covers clinical and public-health topics, its screening is deliberately stricter — submissions undergo additional review for content that could directly influence patient behaviour or clinical practice, and certain categories (such as case reports without a clear scientific contribution) are restricted or excluded outright.

    The same “originator, not owner” caution applies here as everywhere in preprint literature: a medRxiv posting is not evidence of clinical validation and should not be treated as equivalent to a peer-reviewed clinical trial report or a regulatory submission.

    What happens to a preprint after it’s screened and posted

    Once posted, a bioRxiv preprint is permanent and citable. It receives a DOI immediately, cannot be withdrawn once published, and authors can post revised versions that retain the same DOI. Authors typically submit the same manuscript to a journal in parallel or afterwards, where it then enters that journal’s own peer-review process.

    bioRxiv operates a “bioRxiv-to-journal” (B2J) transfer service with more than 300 partner journals — including Cell Reports, PLOS Biology, Genetics in Medicine, and Molecular Biology of the Cell — allowing authors to send a screened preprint directly into a journal’s submission and peer-review pipeline without re-uploading files. This accelerates the path from preprint to certified publication but does not shortcut peer review itself.

    • Readers can post public comments, moderated to professional standards
    • bioRxiv reserves the right to remove plagiarised material or work found to breach research-integrity standards after posting
    • A link to the eventual published version is added automatically, usually within a few weeks of journal publication

    Common questions about bioRxiv and peer review

    Is bioRxiv credible?

    bioRxiv is a credible, widely used distribution channel run by a respected non-profit, but credibility of the platform is separate from validity of any individual manuscript. Screening filters out plagiarism and ethical breaches; it does not certify scientific quality, so each preprint must be read critically on its own merits.

    Is it okay to cite bioRxiv?

    Yes — bioRxiv preprints receive a DOI and are formally citable as part of the scientific record. Most style guides and journals require the citation to note explicitly that the source is an unrefereed preprint, so readers understand it has not passed formal peer review.

    Is a preprint a reliable source?

    A preprint can be a reliable indicator of ongoing research but is not a validated source in the way a peer-reviewed article is. Reliability depends on the specific manuscript — its methods, transparency, and any subsequent independent review — not on the preprint server’s basic screening alone.

    Is bioRxiv considered published?

    bioRxiv preprints are publicly posted and citable, but they are not “published” in the traditional peer-reviewed sense used by journals, funders, and most academic assessment exercises. Many institutions and funders explicitly distinguish preprints from peer-reviewed publications in reporting requirements.

    Implications for authors, readers, and institutions

    For authors, bioRxiv’s fast, lightly gated screening is the trade-off that makes rapid dissemination possible — but it also means responsibility for accuracy sits with the authors, not the platform, until formal peer review occurs. For readers and journalists, the practical rule is definitive: treat unreviewed bioRxiv claims as provisional, check whether a published, peer-reviewed version exists via the automatic journal link, and note preprint status explicitly whenever citing or reporting on one. For institutions building research-integrity or preprint-citation policies, bioRxiv’s own screening criteria — plagiarism, scope, dual-use risk, and patient confidentiality — are a useful documented baseline to reference, precisely because they are narrow and clearly bounded rather than a substitute for peer review.

    As preprint volume continues to grow across the life sciences, the distinction between “screened” and “peer-reviewed” is likely to matter more, not less — particularly as overlay review services like eLife’s Preprint Review and Review Commons expand the space between the two.